PMS Registry
Company Name
Gilead Sciences Hong Kong Limited, Taiwan Branch
Protocol Number
GS-TW-380-5727
Title of Study
Multi-country, non-interventional, cohort study of the effectiveness, safety, adherence, and health-related quality of life in HIV-1 infected adult patients receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Asia.
Primary Objective
To evaluate HIV-1 RNA suppression, defined as HIV 1 RNA <50 copies/mL, at 12 months after initiating or switching to B/F/TAF
Number of Sites
14
Period of Study
From:2021 Q1 to:End of data collection: Q4 2023; Final Clinical Study Report: Q2 2024
Number of Patients
350人
IRB Approval Date
Changhua Christian Hospital:2020/12/09
Kaohsiung Medical Chung Ho Memorial University Hospital:2020/10/27
National Taiwan University Hospital:2020/11/13
Far Eastern Memorial Hospital:2021/04/20
Taoyuan General Hospital: 2021/04/19
Kaohsiung Veterans General Hospital:2020/11/18
Publication Plan / Date
Taiwan AIDS Society: 2023; Asia-Pacific AIDS & Co-infection Conference, APACC: 2023; Taiwan AIDS Society: 2024; Asia-Pacific AIDS & Co-infection Conference, APACC: 2024